Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases [Yahoo! Finance]
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: Yahoo! Finance
Expand bexobrutideg into autoimmune and inflammatory indications, targeting IND submission in 2026 with a new tablet formulation Advance a growing portfolio of partnered inflammation and immunology programs, including potent and selective degraders of IRAK4 and STAT6 Leverage DEL-AI platform to drive discovery against high-value targets across internal and partnered programs BRISBANE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today highlighted the Company's achievements in 2025 and outlined key objectives and anticipated milestones for 2026, which will be the subject of Nurix's corporate update at the 44th Annual J.P. Morgan Healthcare Conference today at 4:30 p.m. PT, in San Francisco. “2025 was a defining year for Nurix, having advanced our potentially be
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Nurix Therapeutics: Why This Company Could Double In Value? [Seeking Alpha]Seeking Alpha
- Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune DiseasesGlobeNewswire
- Nurix Therapeutics (NASDAQ:NRIX) was given a new $36.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.MarketBeat
- Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics' Degrader Platform (NRIX)? [Yahoo! Finance]Yahoo! Finance
NRIX
Earnings
- 10/9/25 - Miss
NRIX
Sec Filings
- 1/12/26 - Form 8-K
- 12/18/25 - Form 4
- 12/18/25 - Form 144
- NRIX's page on the SEC website